Journal Article

Gentamicin and Tetracyclines for the Treatment of Human Plague: Review of 75 Cases in New Mexico, 1985–1999

L. Lucy Boulanger, Paul Ettestad, John D. Fogarty, David T. Dennis, Donald Romig and Gregory Mertz

in Clinical Infectious Diseases

Published on behalf of Infectious Diseases Society of America

Volume 38, issue 5, pages 663-669
Published in print March 2004 | ISSN: 1058-4838
Published online March 2004 | e-ISSN: 1537-6591 | DOI: http://dx.doi.org/10.1086/381545
Gentamicin and Tetracyclines for the Treatment of Human Plague: Review of 75 Cases in New Mexico, 1985–1999

More Like This

Show all results sharing these subjects:

  • Infectious Diseases
  • Immunology
  • Public Health and Epidemiology
  • Microbiology

GO

Show Summary Details

Preview

Streptomycin, an antimicrobial with limited availability, is the treatment of choice for plague, a fulminating and potentially epidemic disease that poses a bioterrorism concern. We evaluated the efficacy of gentamicin and tetracyclines for treating human plague. A medical record review was conducted on all 75 patients with plague who were reported in New Mexico during 1985–1999. Fifty patients were included in an analysis that compared streptomycin-treated patients (n = 14) with those treated with gentamicin and/or a tetracycline (n = 36). The mean numbers of fever days, hospital days, and complications and the number of deaths did not differ between patients treated with streptomycin and those treated with gentamicin. One patient who received tetracycline alone experienced a serious complication. Gentamicin alone or in combination with a tetracycline was as efficacious as streptomycin for treating human plague. The efficacy of a tetracycline alone could not be determined from the study.

Journal Article.  4069 words.  Illustrated.

Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.